Document is current

Article History

Received: 3 October 2025

Accepted: 5 November 2025

First Online: 8 December 2025

Declarations

:

: M. J. Battista reports honoraria and expenses from Astra Zeneca, EISAI, GSK and MSD, and consultant activity to Eisai, GSK, and MSD. Furthermore, he has received research funding by Novartis. None were related to this study. K. Gillen reports personal fees by Clovis Oncology, AstraZeneca, Pharma Mar, MSD, GSK, Novartis and Eisai, not related to this trial. A. Hasenburg reports honoraria and expenses from AstraZeneca, Art Tempi, Celgen, GSK, Lilly, LEO Pharma, MedConcept GmbH, Med update GmbH, Medical Event Solution GmbH, Pfizer, PharmaMar GmbH, Pierre Fabre Pharma GmbH, Roche Pharma AG, Streamedup!GmbH, Tesario as well as work as a consultant to AstraZeneca, GSK, LEO Pharma, Lilly, MSD PharmaMar, Roche, Pfizer, Streamedup!GmbH, Tesario. None were related to this study. V. Linz reports personal honoraria and expenses from Novartis and Lilly. None were related to this study. M. Mohr reports personal fees from Pfizer, Novartis and Bristol Myers Squibb. None were related to this study. Marcus Schmidt reports honoraria and expenses from AstraZeneca, BioNTech, Daiichi Sankyo, Eisai, Lilly, MSD, Novartis, Pantarhei Bioscience, Pfizer, Pierre Fabre, Roche, SeaGen, Gilead, Amgen, Menarini Stemline. His institution has received research funding from AstraZeneca, BioNTech, Eisai, Genentech, German Breast Group, Novartis, Palleos, Pantarhei Bioscience, Pierre Fabre, and SeaGen. In addition, he has a patent for EP 2390370 B1 and a patent for EP 2951317 B1 issued. None were related to this study.